Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
3.34
-0.06 (-1.76%)
Market open: Aug 12, 2026, 3:32 PM EDT
3.46
+0.06 (1.76%)
Previous after-hours: Aug 11, 2026, 7:34 PM EDT
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company’s lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company has a strategic collaboration with PsyLabs to produce Ibogaine. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
| Name | Position |
|---|---|
| Dr. Neil Maresky M.D. | Global Head of Clinical Development |
| Mr. Jody Aufrichtig | Co-Founder, Executive Chairman & CEO |
| Mr. Warwick Ron Corden-Lloyd | CFO & Director |
| Ms. Taryn Vos | General Counsel |
| Date | Type | Document |
|---|---|---|
| 2026-08-06 | 6-K | ea0300579-6k_psyence.htm |
| 2026-06-22 | 20-F | ea0294983-20f_psyence.htm |
| 2026-06-05 | 6-K | ea0293772-6k_psyence.htm |
| 2026-04-23 | 6-K | ea0287437-6k_psyence.htm |
| 2026-04-20 | 6-K | ea0286941-6k_psyence.htm |
| 2026-04-17 | 6-K | ea0286845-6k_psyence.htm |
| 2026-04-15 | 6-K | ea0286375-6k_psyence.htm |
| 2026-03-02 | 6-K | ea0279122-6k_psyence.htm |
| 2026-02-20 | 6-K | ea0277699-6k_psyence.htm |
| 2026-02-19 | 6-K | ea0277000-6k_psyence.htm |